Select Publications

Journal articles

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2024, 'Author Correction: A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models (Scientific Reports, (2023), 13, 1, (15769), 10.1038/s41598-023-42486-3)', Scientific Reports, 14,

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2023, 'A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models', Scientific Reports, 13,

Phan Z; Ford CE; Caldon CE, 2023, 'DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review', Pharmacological Research, 196,

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561,

Weir A; Kang EY; Meagher NS; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Gentry-Maharaj A; Ryan A; Singh N; Widschwendter M; Alsop J; Anglesio MS; Beckmann MW; Berger J; Bisinotto C; Boros J; Brand AH; Brenton JD; Brooks-Wilson A; Carney ME; Cunningham JM; Cushing-Haugen KL; Cybulski C; Elishaev E; Erber R; Fereday S; Fischer A; Paz-Ares L; Gayarre J; Gilks BC; Grube M; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Heublein S; Huang Y; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kommoss FKF; Koziak JM; Kraemer B; Le ND; Lesnock J; Lester J; Lubiński J; Menkiszak J; Ney B; Olawaiye A; Orsulic S; Osorio A; Robles-Díaz L; Ruebner M; Shah M; Sharma R; Shvetsov YB; Steed H; Talhouk A; Taylor SE; Traficante N; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido dos Reis FJ; Cook LS; DeFazio A; Bowtell D; DeFazio A; Traficante N; Fereday S; Brand A; Harnett P; Sharma R; Doherty JA; Fasching PA; García MJ; Goode EL; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kommoss S; Modugno F; Schildkraut JM; Sinn HP; Staebler A; Kelemen LE; Ford CE; Menon U; Pharoah PDP; Köbel M, 2023, 'Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study', British Journal of Cancer, 128, pp. 137 - 147,

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2022, 'Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target (Scientific Reports, (2020), 10, 1, (13906), 10.1038/s41598-020-70924-z)', Scientific Reports, 12,

Henry CE; Llamosas E; Djordjevic A; Hacker NF; Ford CE, 2022, 'Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer (Oncogenesis, (2016), 5, 5, (e226), 10.1038/oncsis.2016.32)', Oncogenesis, 11,

Madani D; John M; Satgunaseelan L; Shivalingam B; Ford C, 2022, 'BIOM-11. ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER', Neuro-Oncology, 24, pp. vii6 - vii6,

Yuwono NL; Alonso A; Abbott J; Houshdaran S; Henry CE; Rodgers R; Ford CE; Warton K, 2022, 'Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis', Human Reproduction, 37, pp. 2560 - 2569,

Werner B; Warton K; Ford CE, 2022, 'Endogenous cell-free DNA in fetal bovine serum introduces artifacts to in vitro cell-free DNA models', BioTechniques, 73, pp. 219 - 226,

John M; Ford CE, 2022, 'Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1', Biomedicines, 10,

Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ, 2022, 'Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival', Cancers, 14,

Fisher T; Ford CE; Warton K, 2022, 'Recovery Efficiency of Cell-Free DNA After Bisulfite Conversion', Clinical chemistry, 68, pp. 1219 - 1220,

Yuwono NL; Boyd MAA; Henry CE; Werner B; Ford CE; Warton K, 2022, 'Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form', Clinical Chemistry and Laboratory Medicine, 60, pp. 1287 - 1298,

Liu D; Kaufmann GF; Breitmeyer JB; Dickson KA; Marsh DJ; Ford CE, 2022, 'The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells', Pharmaceutics, 14,

Alonso A; Yuwono NL; Houshdaran S; Abbott J; Rodgers R; Ford CE; Warton K, 2022, 'Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis', Reproductive BioMedicine Online, 44, pp. 495 - 503,

Werner B; Warton K; Ford CE, 2022, 'Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology', Cancers, 14,

Liu D; Sharbeen G; Phillips P; Johns AL; Gill AJ; Chantrill LA; Timpson P; Chou A; Pajic M; Dwarte T; Herrmann D; Vennin C; Cox TR; Pereira B; Ritchie S; Reed DA; Chambers CR; Metcalf X; Nobis M; Waddell N; Pearson JV; Patch AM; Nones K; Newell F; Mukhopadhyay P; Addala V; Kazakoff S; Holmes O; Leonard C; Wood S; Grimmond SM; Hofmann O; Samra JS; Pavlakis N; Arena J; High HA; Asghari R; Merrett ND; Das A; Cosman PH; Ismail K; Stoita A; Williams D; Spigellman A; Lam VW; McLeod D; Kirk J; Kench JG; Grimison P; Sandroussi C; Goodwin A; Mead RS; Tucker K; Andrews L; Texler M; Forrest C; Ballal M; Fletcher D; Beilin M; Feeney K; Epari K; Mukhedkar S; Zeps N; Nguyen NQ; Ruszkiewicz AR; Worthley C; Chen J; Brooke-Smith ME; Papangelis V; Clouston AD; Barbour AP; O’Rourke TJ; Fawcett JW; Slater K; Hatzifotis M; Hodgkinson P; Nikfarjam M; Eshleman JR; Hruban RH; Wolfgang CL; Scarpa A; Lawlor RT; Corbo V; Bassi C; Biankin AV; Jamieson NB; Chang DK; Dreyer SB; Ford CE, 2021, 'ROR1 and ROR2 expression in pancreatic cancer', BMC Cancer, 21,

Joshi N; Liu D; Dickson KA; Marsh DJ; Ford CE; Stenzel MH, 2021, 'An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles', Journal of Materials Chemistry B, 9, pp. 9123 - 9135,

Yuwono NL; Warton K; Ford CE, 2021, 'The influence of biological and lifestyle factors on circulating cell-free dna in blood plasma', eLife, 10,

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727,

Hagstrom AD; Yuwono N; Warton K; Ford CE, 2021, 'Sex Bias in Cohorts Included in Sports Medicine Research', Sports Medicine, 51, pp. 1799 - 1804,

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276,

Yuwono NL; Henry CE; Ford CE; Warton K, 2021, 'Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation', PLoS ONE, 16,

Liu D; Enriquez L; Ford CE, 2021, 'Ror2 is epigenetically regulated in endometrial cancer', Cancers, 13, pp. 1 - 16,

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2020, 'ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target', Scientific Reports, 10,

Ford CE; Werner B; Hacker NF; Warton K, 2020, 'The untapped potential of ascites in ovarian cancer research and treatment', British Journal of Cancer, 123, pp. 9 - 16,

Warton K; Xu Y; Ford CE, 2020, 'Target sequence heterogeneity causes the 'hook effect' in fluorescent dye-based quantitative PCR', BioTechniques, 69, pp. 81 - 84,

Werner B; Yuwono NL; Henry C; Gunther K; Rapkins RW; Ford CE; Warton K, 2019, 'Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight', PLoS ONE, 14,

Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH, 2019, 'A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles', Biomaterials Science, 7, pp. 1652 - 1660,

Huynh KT; Van Zuylen WJ; Ford CE; Rawlinson WD, 2019, 'Selective modulation of wnt-binding receptor tyrosine kinase ROR2 expression by human cytomegalovirus regulates trophoblast migration', Journal of General Virology, 100, pp. 99 - 104,

Coopes A; Henry CE; Llamosas E; Ford CE, 2018, 'An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target', Endocrine-Related Cancer, 25, pp. R647 - R662,

Cortesi M; Llamosas E; Henry CE; Kumaran RYA; Ng B; Youkhana J; Ford CE, 2018, 'I-AbACUS: A Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays', Scientific Reports, 8,

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584,

Warton K; Yuwono NL; Cowley MJ; McCabe MJ; So A; Ford CE, 2017, 'Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma', Molecular Diagnosis and Therapy, 21, pp. 563 - 570,

Henry CE; Emmanuel C; Lambie N; Loo C; Kan B; Kennedy CJ; de Fazio A; Hacker NF; Ford CE, 2017, 'Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer', Translational Oncology, 10, pp. 346 - 356,

Henry C; Hacker N; Ford C, 2017, 'Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis', Oncotarget, 8, pp. 112727 - 112738,

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv : an international journal of pathology, 470, pp. 99 - 108,

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717,

Hesson LB; Ng B; Zarzour P; Srivastava S; Kwok CT; Packham D; Nunez AC; Beck D; Ryan R; Dower A; Ford CE; Pimanda JE; Sloane MA; Hawkins NJ; Bourke MJ; Wong JWH; Ward RL, 2016, 'Integrated genetic, epigenetic, and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumors', Molecular Cancer Research, 14, pp. 1217 - 1228,

Ma S; srivastava S; llamosas E; hawkins N; hesson L; ward R; Ford C, 2016, 'ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.', BMC Cancer,

van Zuylen W; Ford C; Rawlinson W, 2016, 'Comment on: Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia', The Journal of Maternal-Fetal and Neonatal Medicine,

vanZuylen WJ; Rawlinson WD; Ford C, 2016, 'The Wnt pathway: a key network in cell signalling dysregulated by viruses.', Reviews in Medical Virology,

Henry C; ford C; hacker N; Djordjevic A; Llamosas E, 2016, 'Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.', Oncogenesis,

Henry C; Llamosas E; Djordjevic A; Hacker N; Ford C, 2016, 'Targeting the RB-E2F pathway in breast cancer', Oncogene,

van Zuylen WJ; Ford CE; Wong DDY; Rawlinson WD, 2016, 'Human cytomegalovirus modulates expression of noncanonical Wnt receptor ROR2 to alter trophoblast migration', Journal of Virology, 90, pp. 1108 - 1115,

Naumann F; Yang J-L; Thai T; Ford C; Polly P, 2016, 'Virtual patient consultations and the use of an ePortfolio assessment to support student learning of integrated professional skills', FOCUS ON HEALTH PROFESSIONAL EDUCATION-A MULTIDISCIPLINARY JOURNAL, 17, pp. 69 - 81,

Ford CE; Henry C; Llamosas E; Djordjevic A; Hacker N, 2016, 'Wnt signalling in gynaecological cancers: A future target for personalised medicine?', Gynecologic Oncology, 140, pp. 345 - 351,


Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, 141, pp. 243 - 254,

Back to profile page